Bibliography
- Tsai SF, Cheng CY, Shu KH, Wu MJ. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database. Transplant Proc 2012;44(1):190-2
- CellCept (mycophenolate mofetil). FDA safety alert for human medical products. FDA, Washington, DC; 2008. Available from: http://www.fda.gov/downloads/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm136360.pdf [Last accessed 21 August 2009]
- Tönshoff B, David-Neto E, Ettenger R, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando) 2011;25(2):78-89
- Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando) 2011;25(2):47-57
- Ceschi A, Gregoriano C, Rauber-Lüthy C, et al. Acute mycophenolate overdose: case series and systematic literature analysis. Expert Opin Drug Saf 2014;13(5):525-34
- Sunder-Plassmann G, Reinke P, Rath T, et al. Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. Transpl Int 2012;25(6):680-6
- Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14(2):100-4
- Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 2008;30(2):138-42
- Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 2004;36(5):1327-31
- Kaminska J, Glyda M, Sobiak J, Chrzanowska M. Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment. Arch Med Sci 2012;29;8(1):88-96
- Le Meur Y, Borrows R, Pescovitz MD, et al. Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplant Rev (Orlando) 2011;25(2):58-64
- Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int 2004;17(3):120-5
- Filler G, Sharma AP, Levy DM, Yasin A. Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease. Pediatr Rheumatol Online J 2010;8(1):1
- de Winter BC, van Gelder T, Mathot RA, et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009;31(5):585-91
- Sommerer C, Muller-Krebs S, Schaier M, et al. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010;69(4):346-57
- Filler G, Vinks AA, Huang SH, et al. Exposure on modified release and regular Tacrolimus. Ther Drug Monit 2013. [ Epub ahead of print]
- NAPRTCS. 2010. Available from: https://web.emmes.com/study/ped/annlrept/2010_Report.pdf [Accessed 16 February 2014]
- Filler G, Buffo I. Safety considerations with mycophenolate sodium. Expert Opin Drug Saf 2007;6(4):445-9
- Filler G, Lathia A, LeBlanc C, Christians U. Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. Pediatr Nephrol 2006;21(8):1206-8